NCT03961698: Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)

NCT03961698
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Therapeutic Antibody, Chemotherapy, Immunotherapy, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior chemotherapy or targeted systemic therapy for metastatic TNBC; Patients with any history of, or currently active, brain or leptomeningeal metastases
https://ClinicalTrials.gov/show/NCT03961698

Comments are closed.

Up ↑